Bronchodilators Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The bronchodilators market size was valued at USD 29.30 Billion in 2024 , driven by the rising incidence of chronic lung diseases like COPD and asthma across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2025-2034, with the values likely to rise from USD 45.94 Billion by 2034 .
Bronchodilators: Introduction
A bronchodilator is a medication that helps in the relaxation of the muscles around the bronchi, facilitating easy breathing. It is usually used to relieve the symptoms of asthma, COPD (chronic obstructive pulmonary disease) and other lung diseases. A bronchodilator helps clean the mucus from lungs, allowing it to move freely and get out of the body easily.
There are two forms, mainly short-acting bronchodilators that are effective for 3-6 hours while long-acting bronchodilators that provide help up to 12 hours. They are available as inhalers and nebulizers.
Bronchodilators Market Analysis
With the emergence of COVID-19, the bodies have become more susceptible to chronic respiratory illnesses. β2 adrenoceptor agonists bronchodilators have also found their application as an alternative treatment for treating COVID infected patients, as a result, bronchodilators market demand has seen an upswing in the historic period.
The incidence of chronic lung diseases has led to an increased demand for quality treatment for patients. Bronchodilators are still widely used to treat both COPD and asthma, hence, there have been several new advancements in the existing technology. A contemporary approach to formulate a new dual bronchodilator therapy is in the works. This drug class called MABA has both mAChR antagonism and β2-agonist activity in one molecule. It is believed to be better than the existing combinations due to its ‘triple therapy’ (treatment alternative for COPD) feature. The MABA Batefenterol is under an advanced clinical development stage.
Bronchodilator drugs are also used in combinations to treat lung diseases. For instance, AstraZenenca got the first and only asthma exacerbation risk reducing medication Airsupra (PT027) approved by the FDA in January 2023.It is the first ever drug that contains a combination of albuterol (β2 adrenergic agonist) and budesonide (corticosteroid). With increased application and demand, it is a clear indicator that bronchodilator market growth is certain in the upcoming years.
Bronchodilators Market Segmentation
"Bronchodilators Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
It is estimated that over 300 million asthma patients carry the burden of high morbidities and mortalities across the world. As a result, the bronchodilator market value has risen, with the vision to mitigate the number of morbidities associated with chronic respiratory diseases. The Asia Pacific region is expected to experience rapid growth in terms of market share owing to the presence of a geriatric population in the region. As a precautionary measure, the governments are more alert and working regularly by setting up several awareness campaigns.
The United States is anticipated to lead the bronchodilator market share, which is influenced by the existence of several healthcare leaders in the area. United States healthcare industry is always thriving to bring new innovations in the market. For instance, in a recent trial, Sanofi's Dupixent® showcased significant clinical potential to reduce COPD aggravations by 30%. This indicates that the country is set to experience the latest technological advances exclusively.
Bronchodilators Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Bronchodilators: Introduction
A bronchodilator is a medication that helps in the relaxation of the muscles around the bronchi, facilitating easy breathing. It is usually used to relieve the symptoms of asthma, COPD (chronic obstructive pulmonary disease) and other lung diseases. A bronchodilator helps clean the mucus from lungs, allowing it to move freely and get out of the body easily.
There are two forms, mainly short-acting bronchodilators that are effective for 3-6 hours while long-acting bronchodilators that provide help up to 12 hours. They are available as inhalers and nebulizers.
Bronchodilators Market Analysis
With the emergence of COVID-19, the bodies have become more susceptible to chronic respiratory illnesses. β2 adrenoceptor agonists bronchodilators have also found their application as an alternative treatment for treating COVID infected patients, as a result, bronchodilators market demand has seen an upswing in the historic period.
The incidence of chronic lung diseases has led to an increased demand for quality treatment for patients. Bronchodilators are still widely used to treat both COPD and asthma, hence, there have been several new advancements in the existing technology. A contemporary approach to formulate a new dual bronchodilator therapy is in the works. This drug class called MABA has both mAChR antagonism and β2-agonist activity in one molecule. It is believed to be better than the existing combinations due to its ‘triple therapy’ (treatment alternative for COPD) feature. The MABA Batefenterol is under an advanced clinical development stage.
Bronchodilator drugs are also used in combinations to treat lung diseases. For instance, AstraZenenca got the first and only asthma exacerbation risk reducing medication Airsupra (PT027) approved by the FDA in January 2023.It is the first ever drug that contains a combination of albuterol (β2 adrenergic agonist) and budesonide (corticosteroid). With increased application and demand, it is a clear indicator that bronchodilator market growth is certain in the upcoming years.
Bronchodilators Market Segmentation
"Bronchodilators Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Beta-Adrenergic Bronchodilators
- Xanthine Derivatives
- Anticholinergic Bronchodilators
- Others
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergic Reactions
- Breathing Problem
- Others
- Oral
- Parenteral
- Inhalational
- Others
- Hospitals
- Speciality Clinics
- Home Healthcare
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
It is estimated that over 300 million asthma patients carry the burden of high morbidities and mortalities across the world. As a result, the bronchodilator market value has risen, with the vision to mitigate the number of morbidities associated with chronic respiratory diseases. The Asia Pacific region is expected to experience rapid growth in terms of market share owing to the presence of a geriatric population in the region. As a precautionary measure, the governments are more alert and working regularly by setting up several awareness campaigns.
The United States is anticipated to lead the bronchodilator market share, which is influenced by the existence of several healthcare leaders in the area. United States healthcare industry is always thriving to bring new innovations in the market. For instance, in a recent trial, Sanofi's Dupixent® showcased significant clinical potential to reduce COPD aggravations by 30%. This indicates that the country is set to experience the latest technological advances exclusively.
Bronchodilators Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceutical PLC
- Amneal Pharmaceuticals LLC
- Aurobindo Pharma
- Johnsons & Johnsons Services Pvt Ltd
- GSK Plc
- Thermo Fisher Scientific Inc.
- Siemens
- Cipla Inc.
- AstraZeneca
- Mylan N.V.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Bronchodilators Market Overview
- 3.1 Global Bronchodilators Market Historical Value (2018-2024)
- 3.2 Global Bronchodilators Market Forecast Value (2025-2034)
- 4 Global Bronchodilators Market Landscape
- 4.1 Global Bronchodilators Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Bronchodilators Product Landscape
- 4.2.1 Analysis by Drug Class
- 4.2.2 Analysis by Indication
- 4.2.3 Analysis by Route of Administration
- 5 Global Bronchodilators Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Bronchodilators Market Segmentation
- 6.1 Global Bronchodilators Market by Type
- 6.1.1 Market Overview
- 6.1.2 Beta-Adrenergic Bronchodilators
- 6.1.3 Xanthine Derivatives
- 6.1.4 Anticholinergic Bronchodilators
- 6.1.5 Others
- 6.2 Global Bronchodilators Market by Indication
- 6.2.1 Market Overview
- 6.2.2 Asthma
- 6.2.3 Chronic Obstructive Pulmonary Disease (COPD)
- 6.2.4 Allergic Reactions
- 6.2.5 Breathing Problem
- 6.2.6 Others
- 6.3 Global Bronchodilators Market by Route of Administration
- 6.3.1 Market Overview
- 6.3.2 Oral
- 6.3.3 Parenteral
- 6.3.4 Inhalational
- 6.3.5 Others
- 6.4 Global Bronchodilators Market by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals
- 6.4.3 Speciality Clinics
- 6.4.4 Home Healthcare
- 6.4.5 Others
- 6.5 Global Bronchodilators Market by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Bronchodilators Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Bronchodilators Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Bronchodilators Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Bronchodilators Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Bronchodilators Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
- 14.1 Analysis by Trial Registration Year
- 14.2 Analysis by Trial Status
- 14.3 Analysis by Trial Phase
- 14.4 Analysis by Therapeutic Area
- 14.5 Analysis by Geography
- 15 Funding & Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.1 US FDA
- 17.1.2 EU EMA
- 17.1.3 INDIA CDSCO
- 17.1.4 JAPAN PMDA
- 17.1.5 Others
- 18 Supplier Landscape
- 18.1 Bayer AG
- 18.1.1 Financial Analysis
- 18.1.2 Product Portfolio
- 18.1.3 Demographic Reach and Achievements
- 18.1.4 Mergers and Acquisitions
- 18.1.5 Certifications
- 18.2 Teva Pharmaceutical Industries Ltd.
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Mergers and Acquisitions
- 18.2.5 Certifications
- 18.3 Sun Pharmaceutical Industries Ltd.
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Mergers and Acquisitions
- 18.3.5 Certifications
- 18.4 Hikma Pharmaceutical PLC
- 18.4.1 Financial Analysis
- 18.4.2 Financial Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Mergers and Acquisitions
- 18.4.5 Certifications
- 18.5 Amneal Pharmaceuticals LLC
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Mergers and Acquisitions
- 18.5.5 Certifications
- 18.6 Aurobindo Pharma
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Mergers and Acquisitions
- 18.6.5 Certifications
- 18.7 Johnsons & Johnsons Services Pvt Ltd
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 GSK Plc
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Mergers and Acquisitions
- 18.8.5 Certifications
- 18.9 Thermo Fisher Scientific Inc.
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Mergers and Acquisitions
- 18.9.5 Certifications
- 18.10 Siemens
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Mergers and Acquisitions
- 18.10.5 Certifications
- 18.11 Cipla Inc.
- 18.11.1 Financial Analysis
- 18.11.2 Product Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Mergers and Acquisitions
- 18.11.5 Certifications
- 18.12 AstraZeneca
- 18.12.1 Financial Analysis
- 18.12.2 Product Portfolio
- 18.12.3 Demographic Reach and Achievements
- 18.12.4 Mergers and Acquisitions
- 18.12.5 Certifications
- 18.13 Mylan N.V.
- 18.13.1 Financial Analysis
- 18.13.2 Product Portfolio
- 18.13.3 Demographic Reach and Achievements
- 18.13.4 Mergers and Acquisitions
- 18.13.5 Certifications
- 19 Global Bronchodilators Market - Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 21 Company Competitiveness Analysis (Additional Insight)
- 21.1 Very Small Companies
- 21.2 Small Companies
- 21.3 Mid-Sized Companies
- 21.4 Large Companies
- 21.5 Very Large Companies
- 22 Payment Methods (Additional Insight)
- 22.1 Government Funded
- 22.2 Private Insurance
- 22.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
